| Autor: |
Taito Fukushima, Manabu Morimoto, Makoto Ueno, Kousuke Kubota, Haruki Uojima, Hisashi Hidaka, Makoto Chuma, Kazushi Numata, Kota Tsuruya, Shunji Hirose, Tatehiro Kagawa, Nobuhiro Hattori, Tsunamasa Watanabe, Kotaro Matsunaga, Kouji Yamamoto, Katsuaki Tanaka, Shin Maeda |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
JGH Open, Vol 6, Iss 1, Pp 29-35 (2022) |
| Druh dokumentu: |
article |
| ISSN: |
2397-9070 |
| DOI: |
10.1002/jgh3.12691 |
| Popis: |
Abstract Aims There is a paucity of comparative data on the use of sorafenib and lenvatinib for unresectable hepatocellular carcinoma. We assessed the real‐world treatment outcomes between using sorafenib and lenvatinib for unresectable hepatocellular carcinoma in the multiple molecular‐targeted therapy era. Methods and Results We enrolled 386 patients treated with sorafenib or lenvatinib as the first‐line therapy for unresectable hepatocellular carcinoma at multiple centers. Propensity score matching was performed to adjust for differences in baseline and tumor characteristics between the two groups. Propensity score matching identified 110 patients in each treatment group. The median overall survival was similar between lenvatinib and sorafenib (14.8 and 13.0 months, respectively; P = 0.352). The median progression‐free survival was longer with lenvatinib than with sorafenib (7.6 and 3.9 months, respectively; P |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Plný text